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Autoantibodies to cellular constituents are the serological hallmark in systemic autoimmune
rheumatic diseases (1). They are often associated with certain diagnosis, clinical features, or disease
activity and considered as clinically useful biomarkers. Autoantibody immunoassays have been
used extensively for over 50 years with continuous changes in technologies and antigens used.
While standard enzyme-linked immunosorbent assay (ELISA) is still commonly used in practice,
migration to multiplex immunoassays is the direction that many companies and laboratories are
moving toward. Althoughmultiplex assays havemany advantages over conventional assays, there are
also problems that may cause confusions among clinicians and researchers. In this Opinion Article,
advantages and current problems in the use of multiplex immunoassays are discussed.
Multiplex Assays to Detect Autoantibodies
Multiplex autoantibody assays are ones that can detect many specific autoantibodies in a single run
whereas a traditional ELISA uses a single antigen to detect only a single specificity of autoantibodies.
Thus, in a multiplex assay, combination of recombinant or native antigens or antigenic peptide
is used to detect many specific autoantibodies all at once. Immunoassays using crude antigens
are not generally considered as multiplex assays even though classical double immunodiffusion or
immunoprecipitation can also detectmany specific autoantibodies in a single run. Types ofmultiplex
assays include Line immunoassay (LIA), multiplex beads assay, and solid-phase antigen microarray.
LIA is somewhat similar to dot blot or western blot as a diluted serum is incubated with a strip
that has several specific antigens in different areas on a strip. In multiplex beads assay, beads with
different sizes and/or fluorochromes with different colors or intensities are coated with different
specific antigens andmixed to allow detection of each specific autoantibody by gating on beads with
certain characteristic. In antigenmicroarrays,manydifferent specific antigens are coated on a slide or
amembrane. These strips,mixture of beads, or a slide/membranewithmultiple antigens is incubated
with a diluted serum, and many specific autoantibodies can be determined simultaneously. The
reasons that multiplex assays are replacing conventional ELISA are to save time, material and labor
cost, and allow efficient handling of a large number of samples to enhance the overall throughput
for companies and laboratories. Results for many autoantibody specificities can be obtained with
overall cost comparable to or less than that for some conventional assays. For clinicians and patients,
expectations are to improve assay sensitivity and specificity as many specificities can be tested using
small amounts of sera in a single run.
With increasing labor cost, a major goal in the commercialization of immunoassays has been
shifted toward cost effectiveness and convenience to handle large number of samples, rather than
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reliability and validated results of the assay. While new multi-
plex immunoassays have certain advantages over conventional
assays, using them with incomplete understanding, or without
validation of the new assay against classic or standard assays, has
causedmany concerns, confusions, and problems in autoantibody
immunoassays for clinicians and patients.
Antinuclear Antibody Screening by
Multiplex Beads Assays
One recent issue in the United States regarding the standard
antinuclear antibody (ANA) screening illustrated the problem
we are facing; the method of screening ANA was switched from
conventional immunofluorescence (IF) assay using ANA slide to
multiplex beads assay without understanding by the clinicians. It
was initially noticed by a group of clinicians based on the negative
results reported in previously ANA positive patients, and the low
prevalence of positive ANA in scleroderma (SSc), polymyosi-
tis/dermatomyositis (PM/DM) and others. Although a beads assay
itself using recombinant or native antigens is a reasonable assay
to detect specific autoantibodies, it is a problem in terminology
when a beads assay using a mixture of a few known autoantigens
was approved by the FDA as “ANA screening test,” which is a term
commonly considered screening of ANA by the classical indirect
IF assay. There was the confusion in an assay that is used for
general screening for many autoantibodies (ANA IF) vs. the one
to detect a few specific autoantibodies (multiplex assay).
In 2009, American College of Rheumatology issued a position
statement that was summarized as the following (2):
 The IF ANA assay is the gold standard for ANA testing with
greater sensitivity than solid-phase assays.
 HEp-2 cells have approximately 100–150 possible autoanti-
gens. These cells are used to detect ANAs by the IF method,
in which both pattern and titer can be described, and to
display a variety of autoantigens not present in multiplex
ANA tests.
 Many commercial laboratories and some hospital laborato-
ries have switched their ANA screening test to solid-phase
immunoassays, such as a multiplex platform. The latter
technique can screen and process large volumes of clinical
specimens more quickly and at less cost than the traditional
IF ANA test using fixed HEp-2 cells as substrate.
 These multiplex assays can detect only the specific autoanti-
bodies directed against the limited number (typically 8–10)
autoantigens that are displayed.
 Laboratories should indicate the method used when report-
ing ANA results.
This issue of discrepancies in ANA reporting was also docu-
mented in several studies. For example, the Bioplex 2200multiplex
beads include dsDNA, Ro60, La, Sm/RNP complex, Sm, chro-
matin, ribosomal P, Ro52, RNP-A, RNP-68kD, Scl-70 (topoiso-
merase I), centromere B, and Jo-1. In one study, lower prevalence
of ANAwas reported by Bioplex 2200 compared to IF ANA in SLE
(3). The difference was more significant in European Americans
compared with other ethnicities, likely to reflect known lower
prevalence of antibodies to the specific antigens included in the
Bioplex. Low prevalence of ANA reported by Bioplex in SSc and
PM/DM was also shown in another article (4). This finding is not
a surprise because, for the detection of SSc antibodies, only Scl-70
and centromere B antigens are included while RNA polymerase
III and SSc-related nucleolar antigens are not included. Similarly,
for the detection of PM/DM antibodies, only Jo-1 antigen is
included in the Bioplex 2200. Thus, only a subset of patients who
have antibodies to these few antigens will be reported positive by
the Bioplex ANA screening. This point was further addressed in
another study that showed prevalence of ANA in SSc patients clas-
sified based on autoantibody specificities. Most of anti-RNP, anti-
Scl-70 or anti-centromere positive samples were positive by mul-
tiplex ANA as expected because the target antigens are included
in multiplex ANA. However, majority of samples negative for
these three specificities or samples positive for nucleolar ANA
or anti-RNA polymerase III were reported negative (5). These
data clearly indicate that replacing ANA screening test by IF with
these multiplex beads assays is inappropriate. This problem may
be partially resolved by not using the generic “ANA screen” to
describe multiplex assays.
Problems in Multiplex Autoantibody Assays
The concept of many multiplex assays is great and there are num-
ber of advantages for multiple assays over conventional assays,
including cost and labor effectiveness, saving amount of sample,
and quick availability of results. Basic principle of the multiplex
assays is the same as conventional immunoassays with the detec-
tion of antibody binding to antigens on beads or plate. Thus, they
should have potential to be as good as conventional assays. How-
ever, the main concern is the quality of multiplex assays that are
commercially available for clinical and research use.Many of them
are released to the market with little or no validation of the results
compared to conventional or gold standard assays. Most inno-
cent clinicians assume that commercially available immunoassays,
including multiplex assays, are validated and reliable, and that
results are comparable to those by conventional assays. Now it
is obviously clear that this is an incorrect and very dangerous
assumption. For example, a significant number of sera positive for
anti-Th/To by immunoprecipitation weremissed by a commercial
LIA on the market (6). Use of new unvalidated microarrays for
research purpose both in human and mouse studies is another
example of problems (7, 8). In these reports, well-established
myositis-specific autoantibodies anti-Jo-1, PL-7, PL-12, and SRP
and SSc-specific anti-Scl-70 were reported positive in SLE sera.
Potential hazards caused by these questionable results from these
unreliable tests are huge including (1) providing inaccurate infor-
mation and confuse clinicians, (2) confusing or interfering with
the well-established clinical significance of these autoantibodies,
and (3) confusing researchers and misleading basic science in
future investigation regarding the mechanisms of autoimmunity.
Another common assumption is that results of the new
immunoassay using recombinant proteins or synthetic autoanti-
gen peptide should reflect the reactivity by conventional or
standard immunoassays. This assumption is often wrong and
it is not a unique problem for many new multiplex assays as
similar problem can be common for some commercial ELISA.
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Characteristic of autoimmune B-cell epitopes is discontinuous
conformation dependent epitopes. Very few synthetic short pep-
tides have proved to be useful as substrate in autoantibody assay.
The C-terminal peptide for ribosomal P antigen and cyclic citrul-
linated peptide for profilaggrin are exceptional cases where they
can be reliable autoantibody assay substrates in many laboratory
settings. Recombinant proteins or synthetic peptides may not
carry most epitopes same as native antigens and yet they can
include epitopes that are not present on native antigens. Thus, the
autoantibody reactivity in sera against these recombinant proteins
or peptides may not correlate with that of native antigens. For
example, it was shown that the reactivity of sera with Sm antigen-
derived peptide PPPGMRPP in immunoassays does not correlate
with the presence of conventional anti-Sm antibodies (1, 9).
Comparisons Between Different Multiplex
Assays and Multiplex Assays vs
Conventional Assays
It is noteworthy that some newly developed immunoassays such
as anti-RNApolymerase III and anti-aminoacyl tRNA synthetases
were carefully validated against a gold standard immunoprecip-
itation assay (10, 11). However, unfortunately many commercial
immunoassays are released to themarket without appropriate val-
idation against conventional or standard assays. There is no stan-
dardization or evaluation betweenmultiplex assays using different
technologies and different antigens, thus the prevalence of specific
autoantibodies are quite different even within different beads
assays (12). In one study using sera from SLE patients, prevalence
of the two most important autoantibodies in SLE, anti-Sm, and -
dsDNA/chromatin, were more than twice different between three
beads assays when same samples were tested (Table 1, left). Anti-
Scl-70 antibodies were detected in 7% of SLE by one of the three
assays tested. This may be related to false positive results by
anti-dsDNA antibody positive SLE patients in certain anti-Scl-70
immunoassay (1). In testing samples from systemic autoimmune
rheumatic diseases, several-fold differences in prevalence were
noted for most of major autoantibody specificities tested.
In another study, two beads assays and LIA were compared and
significant differences in prevalence of anti-dsDNA, Sm, Ro60 and
others were found (Table 1, right) (13). By comparison of beads
assay vs ELISA, significant differenceswere noted for anti-dsDNA,
Sm, and La (14). Surprisingly few studies reported comparison
of multiplex assays vs conventional or standard assays that were
used to define the autoantibody specificity or have been used for
years as a standard assay and considered as a gold standard. In
one study, prevalence by a beads assay was similar to those by a
conventional counter immunoelectrophoresis (CIE) while ELISA
showed ~1.5 times higher prevalence for anti-Sm and U1RNP vs
CIE or beads assay (15).When the results by a beads assay, ELISA,
and CIE were compared using the kappa statistical measure, CIE
and an addressable laser bead immunoassay (ALBIA) had good
correlation whereas the kappa values were lower in anti-Sm and
U1RNP for CIE vs ELISA comparison. These data suggest that the
results by ALBIAmay bemore consistent with those by a standard
CIE assay than ELISA.
Conclusion
Multiplex immunoassays for autoantibodies differ significantly
depending on the manufacturer or kits and do not always show
the intended specificity and sensitivity. These assays should
be validated against a standard assay before releasing to the
market or using in research to avoid confusions among clinicians
and researchers. Post-market evaluation of these technologies
including systematic evaluation and standardization of assays are
warranted.
TABLE 1 | Prevalence of autoantibodies in SLE clinical samples by multiplex assays from two studies.
Copple et al. (12) (%)a Hanly et al. (13) (%)b
SLE, n=64 SLE, n= 192
Manufacturer BMDc INOVAd Athenae Bio-Radf INOVAd Mikrogeng
Type Beads Beads Beads Beads Beads LIA
Specificity
SS-A/Ro60 22 22 18 38:0 37:5 27:6
SS-B/La 5 3 11 23:4 16:1 16:1
Sm 9 11 23 16:7 26:6 30:7
U1RNP 30 23 35 24:0 29:1 29:2
Scl-70 0 0 7 5:2 3:1 0
Jo-1 0 0 0 0:5 1:0 1:0
dsDNA/chr 23 15 34 31:8 na 20:3
aPercentages are approximate reading from a bar graph in Copple et al. (12).
bData for anti-dsDNA are reported in dsDNA/chromatin row.
cBiomedical Diagnostics, FIDIS connective 10.
d INOVA, QUANTA PlexTM ENA8.
e Inverness Medical Professional Diagnostics, AtheNA Multi-Lyte ANA-II test system. Listed as “Athena” to be consistent with graphs in Ref. (12).
fBio-Rad Laboratories, BioPlex 2200.
gMikrogen, recomLine ANA/ENA.
LIA, line immunoassay; chr, chromatin; na, not available.
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